Cellectar Biosciences Inc.

1.52+0.0250+1.68%Vol 64.16K1Y Perf 9.64%
Apr 23rd, 2021 10:44 DELAYED
BID1.51 ASK1.52
Open1.51 Previous Close1.49
Pre-Market- After-Market-
 - -%  - -
Target Price
5.98 
Analyst Rating
Strong Buy 1.00
Potential %
290.16 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Market Cap76.51M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
25.63 
Earnings Date
6th May 2021

Today's Price Range

1.461.55

52W Range

1.012.98

5 Year PE Ratio Range

-3.10-0.7000

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
4.93%
1 Month
-14.37%
3 Months
-23.20%
6 Months
22.13%
1 Year
9.64%
3 Years
-86.45%
5 Years
-91.99%
10 Years
-99.96%

TickerPriceChg.Chg.%
CLRB1.520.02501.68
AAPL133.671.73001.31
GOOG2 293.8325.91001.14
MSFT259.362.19000.85
XOM55.680.41000.74
WFC43.520.82001.92
JNJ165.710.53000.32
FB298.642.12000.71
GE13.540.13000.97
JPM149.572.20001.49
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.15-0.0753.33
Q03 2020-0.15-0.150.00
Q02 2020-0.30-0.2613.33
Q01 2020-0.34-0.42-23.53
Q04 2019-0.36-0.338.33
Q03 2019-0.38-0.42-10.53
Q02 2019-0.60-0.4623.33
Q01 2019-0.50-0.76-52.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.0943.75Positive
6/2021 QR-0.0947.06Positive
12/2021 FY-0.4518.18Positive
12/2022 FY-0.487.69Positive
Next Report Date6th May 2021
Estimated EPS Next Report-0.09
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume64.16K
Shares Outstanding50.50M
Trades Count293
Dollar Volume3.34M
Avg. Volume1.68M
Avg. Weekly Volume327.58K
Avg. Monthly Volume602.42K
Avg. Quarterly Volume1.66M

Cellectar Biosciences Inc. (NASDAQ: CLRB) stock closed at 1.49 per share at the end of the most recent trading day (a 0.68% change compared to the prior day closing price) with a volume of 298.30K shares and market capitalization of 76.51M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Cellectar Biosciences Inc. CEO is James V. Caruso.

The one-year performance of Cellectar Biosciences Inc. stock is 9.64%, while year-to-date (YTD) performance is -28.37%. CLRB stock has a five-year performance of -91.99%. Its 52-week range is between 1.01 and 2.98, which gives CLRB stock a 52-week price range ratio of 25.63%

Cellectar Biosciences Inc. currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 2.06, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -41.93%, a ROC of -108.68% and a ROE of -69.60%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cellectar Biosciences Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. Cellectar Biosciences Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Cellectar Biosciences Inc. is Strong Buy (1), with a target price of $5.98, which is +290.16% compared to the current price. The earnings rating for Cellectar Biosciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cellectar Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cellectar Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.11, ATR14 : 0.16, CCI20 : -18.54, Chaikin Money Flow : -0.04, MACD : -0.18, Money Flow Index : 14.09, ROC : -3.25, RSI : 46.42, STOCH (14,3) : 36.84, STOCH RSI : 1.00, UO : 51.22, Williams %R : -63.16), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cellectar Biosciences Inc. in the last 12-months were: Dov Elefant (Buy at a value of $14 978), James V. Caruso (Buy at a value of $83 551), Jarrod Longcor (Buy at a value of $114 675), Stephen A. Hill (Buy at a value of $19 438)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cellectar Biosciences Inc.

Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124, and CLR 1502.

CEO: James V. Caruso

Telephone: +1 608 441-8120

Address: 100 Campus Drive, Florham Park 07932, NJ, US

Number of employees: 8

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

47%53%

Bearish Bullish

52%48%

News

Stocktwits